|

P-CD19CD20-ALLO1 Cells Clinical Trials

2 actively recruiting trials across 2 locations

Pipeline

Phase 1: 2

Top Sponsors

  • Genentech, Inc.2

Indications

  • Systemic Lupus Erythematosus1
  • Lupus1
  • Multiple Sclerosis1

Birmingham, Alabama1 trial

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

University of Alabama at Birmingham: The Kirklin Clinic

Phase 1

St Louis, Missouri1 trial

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

Washington University School of Medicine

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.